GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EPIRUS Biopharmaceuticals Inc (OTCPK:EPRSQ) » Definitions » Volatility

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Volatility : 90.00% (As of May. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is EPIRUS Biopharmaceuticals Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-29), EPIRUS Biopharmaceuticals's Volatility is 90.00%.


Competitive Comparison of EPIRUS Biopharmaceuticals's Volatility

For the Biotechnology subindustry, EPIRUS Biopharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EPIRUS Biopharmaceuticals's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EPIRUS Biopharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where EPIRUS Biopharmaceuticals's Volatility falls into.



EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


EPIRUS Biopharmaceuticals Volatility Related Terms

Thank you for viewing the detailed overview of EPIRUS Biopharmaceuticals's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
699 Boylston Street, Eighth Floor, Boston, MA, USA, 02116
EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman's disease. The group generally operates through the United States.
Executives
Vincent Aurentz officer: Chief Business Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Thomas A. Shea officer: Chief Financial Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET 8TH FLOOR, BOSTON MA 02116
Amit Munshi director, officer: Chief Executive Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Scott M Rocklage director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark Corrigan director
Geoffrey M Duyk director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Montreux Equity Partners Iv Lp 10 percent owner ONE FERRY BUILDING,, SUITE 255, SAN FRANCISCO CA 94111
5am Ventures Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
5am Co-investors Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Iii, Llc 10 percent owner 2200 SAND HILL ROAD STE 110, MENLO PARK CA 94025
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Headlines

From GuruFocus

CEO of Epirus Biopharmaceuticals Buys 10,000 Shares

By Jennifer Chiou Jennifer Chiou 09-23-2015